USFDA approves Cadila Healthcare’s Moraiya facilities

17 Jul 2012 Evaluate

Cadila Healthcare has received a letter from US Food and Drug Administration (USFDA), conveying that the facilities at Moraiya are acceptable. The USFDA had earlier issued a warning letter to the company but with this it is been resolved.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

The company has posted a rise of 55.30% in its net profit at Rs 139.40 crore for the quarter ended March 31, 2012 as compared to Rs 89.76 crore for the same quarter in the previous year. Total income has increased by 13.95% at Rs 795.86 crore for quarter under review as compared Rs 698.41 crore for the quarter ended March 31, 2011.

Zydus Lifesciences Share Price

884.85 8.75 (1.00%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×